安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Dupilumab (Dupixent): Uses, Dosage, Side Effects, Warnings - Drugs. com
Dupilumab is used to treat atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis The brand name of dupilumab is Dupixent
- Take Action With DUPIXENT® (dupilumab)
Learn more about DUPIXENT® (dupilumab), a prescription medicine FDA-approved to treat nine conditions See if DUPIXENT® may be right for you? Serious side effects can occur Please see Important Safety Information and Prescribing Information and Patient Information on website
- Dupilumab - Wikipedia
Dupilumab is the first treatment for prurigo nodularis approved by the FDA [11] Prurigo nodularis is a rare skin disease that causes hard, itchy lumps (nodules) to form on the skin
- Dupixent: Uses, Dosage, Side Effects, Warnings - Drugs. com
Dupixent (dupilumab) is a biologic injection that works by blocking two inflammatory proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which drive conditions such as eczema, asthma, and nasal polyps
- Dupilumab (subcutaneous route) - Side effects dosage
Dupilumab helps prevent severe asthma attacks (exacerbations) and can improve your breathing This medicine will not relieve an asthma attack that has already started
- Dupixent (Dupilumab) - Uses, Side Effects, and More - WebMD
Overview: Dupixent is used for several conditions, including asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and others It is injected under the skin It works by
- Dupilumab - DermNet
Dupilumab is a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13 Clinical trials of systemic dupilumab in moderate-to-severe atopic dermatitis have demonstrated a marked improvement in patient symptoms, including pruritus and clinically visible disease
- Dupilumab: Mechanism of action, clinical, and translational science
Dupilumab binds to the interleukin (IL)‐4 receptor alpha subunit (IL‐4Rα) that blocks IL‐4 and IL‐13 signaling, two key drivers of type 2 inflammation
|
|
|